Real-World Treatment Patterns and Effectiveness of Targeted and Systemic Therapy in Patients With Advanced Lung Cancer Carrying MET Mutation-Positive
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Gumarontinib (Primary) ; Immunotherapies (Primary) ; Savolitinib (Primary) ; Vebreltinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 19 Sep 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.
- 19 Sep 2024 Planned primary completion date changed from 31 Mar 2024 to 31 Dec 2024.
- 02 Jan 2024 New trial record